

FORM PTO-1595
(Rev. 6-93)

07-21-2003

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office



102501533

ION FORM COVER SHEET
ENTS ONLY

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies): Fujisawa Pharmaceutical Co., Ltd. 7-17-03
Additional name(s) of conveying party(ies) attached?
 Yes No

2. Name and address of receiving party(ies):
Name: Yoshio HAYASHI
Internal Address: 1-8-301 Jounancho
2-chome, Tokushima
Street Address:
City: Tokushima 770 Country: JAPAN Zip:
Additional name(s) & address(es) attached?
 Yes No

OFFICE OF PUBLIC RECORDS
2003 JUL 17 PM 3:00
FINANCE SECTION

3. Nature of Conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other:
Execution Date: June 23, 2003

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____
A. Patent Application No(s):
09/499,765
Additional numbers attached? Yes No

B. Patent No.(s)
6. Total number of applications and patents involved: [1]

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Jun Umemuro
Street Address: Dike, Bronstein, Roberts & Cushman
Intellectual Property Group of
EDWARDS & ANGELL, LLP
P.O. Box 9169
City: Boston State: MA Zip: 02209

7. Total fee (37 CFR 3.41): \$40.00
 Enclosed - Any excess or insufficiency should be credited or debited to deposit account
 Authorized to be charged to deposit account

8. Deposit account number: 04-1105
(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature. *To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*
David G. Conlin (Reg. No. 27,026)
Name of Person Signing

[Signature]
Signature
June 14, 2003
Date

Total number of pages including cover sheet, attachments, and documents:

ASSIGNMENT

KNOW ALL MEN BY THESE PRESENTS, THAT

WHEREAS, Fujisawa Pharmaceutical Co., Ltd., (hereinafter designated as the Assignor) a corporation duly organized under the laws of Japan, and having a regular and established place of business at 4-7, Doshomachi 3-chome, Chuo-ku, Osaka 541-8514 Japan, having an undivided one-half interest in the right, title and interest in United States Patent Application Number 09/499,765, entitled COMPOSITION CONTAINING α -FODRIN OR α -FODRIN FRAGMENT PROTEIN, filed February 8, 2000, and the inventions disclosed therein; and

WHEREAS, Yoshio HAYASHI (hereinafter referred to as the Assignee) of 1-8-301, Jounancho 2-chome, Tokushima, Tokushima 770, Japan, for the benefit of himself, his successors and assigns, is desirous of acquiring the undivided one-half interest in the right, title and interest in and to said invention and in and to any Letters Patent(s) that may be granted therefor in the United States of America; and

NOW, THEREFORE, BE IT KNOWN THAT FOR and in consideration of one dollar and other valuable considerations paid to the Assignor by the Assignee, the receipt of which is hereby acknowledged, the Assignor does hereby sell, assign and transfer unto said Assignee, its undivided one-half interest in the right, title and interest in and to said United States Patent Application Number 09/499,765, and the inventions disclosed therein, in and to any and all Letters Patent(s) which may be granted therefor in the United States of America and its territories, dependencies and possessions, in and to any and all divisions, reissues, continuations and extensions thereof for the full term or terms for which the same may be granted, in and to any and all improvements which are disclosed in said United States Letters Patent, and in and to all parent, substitute, renewal, reissue and reexamined patents which have been or shall be issued in the United States.

Assignor agrees that said Assignee may apply for and receive Letters Patent in its own name; and that, when requested, without charge to but at the expense of said Assignee, its successors, assigns and legal representatives, to carry out in good faith the intent and purpose of this assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue and all other patent applications on any and all said improvements; execute all rightful oaths, assignments, powers of attorney and other papers; communicate to said Assignee, its successors, assigns and legal representatives, all facts known to the undersigned relating to said improvements and the history thereof; and generally do everything possible which said Assignee, its successors, assigns, and legal representatives shall consider desirable for aiding in securing and maintaining proper patent protection for said improvements, and for vesting title

to said improvements and all applications for patents and all patents on said improvements, in said Assignee, its successors, assigns and legal representatives; and the Assignor does hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said U.S. application(s) to said Assignee, its successors and assigns.

Assignor covenants with said Assignee, its successors, assigns and legal representatives that no assignment, grant, mortgage, license or other agreements affecting the rights and property herein conveyed has been made to others by the Assignor, and that full right to convey the same as herein expressed is possessed by the Assignor.

The undersigned hereby grant(s) the law firm of Edwards & Angell, LLP of Boston, Massachusetts, U.S.A. the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

In witness whereof, signed by the undersigned on the date opposite the undersigned name.

Fujisawa Pharmaceutical Co., Ltd.

Signature: Yuji Watanabe
Yuji Watanabe, Director
Intellectual Property

Date: June 23, 2003

* * * * *

Date: June 23, 2003

Witness: Seiji Ejima
Seiji Ejima, Manager